|32.12||-0.8000||-2.43%||Vol 15.97K||1Y Perf 82.19%|
|Apr 16th, 2021 11:17 DELAYED|
|- -%||- -|
|Target Price||73.00||Analyst Rating||Strong Buy 1.00|
|Potential %||125.03||Finscreener Ranking||★★★★+ 56.53|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.49|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 53.51|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||613.94M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||47.25||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-1.72|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||125.78K|
|Avg. Monthly Volume||147.16K|
|Avg. Quarterly Volume||168.43K|
Albireo Pharma Inc. (NASDAQ: ALBO) stock closed at 32.92 per share at the end of the most recent trading day (a 1.64% change compared to the prior day closing price) with a volume of 195.66K shares and market capitalization of 613.94M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Albireo Pharma Inc. CEO is Ronald H.W. Cooper.
The one-year performance of Albireo Pharma Inc. stock is 82.19%, while year-to-date (YTD) performance is -12.24%. ALBO stock has a five-year performance of 188.77%. Its 52-week range is between 17 and 49, which gives ALBO stock a 52-week price range ratio of 47.25%
Albireo Pharma Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 3.55, a price-to-sale (PS) ratio of 90.32, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.26%, a ROC of -48.75% and a ROE of -76.16%. The company’s profit margin is -%, its EBITDA margin is -672.60%, and its revenue ttm is $6.76 Million , which makes it $0.35 revenue per share.
Of the last four earnings reports from Albireo Pharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.72 for the next earnings report. Albireo Pharma Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Albireo Pharma Inc. is Strong Buy (1), with a target price of $73, which is +125.03% compared to the current price. The earnings rating for Albireo Pharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Albireo Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Albireo Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.86, ATR14 : 2.08, CCI20 : -88.48, Chaikin Money Flow : -0.18, MACD : -1.43, Money Flow Index : 35.63, ROC : -3.74, RSI : 50.51, STOCH (14,3) : 22.94, STOCH RSI : 1.00, UO : 34.48, Williams %R : -77.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Albireo Pharma Inc. in the last 12-months were: Jan P. Mattsson (Option Excercise at a value of $39 330), Jan P. Mattsson (Sold 41 470 shares of value $1 615 184 ), Jason G. Duncan (Option Excercise at a value of $84 140), Jason G. Duncan (Sold 4 382 shares of value $193 072 ), Martha Carter (Option Excercise at a value of $886 380), Martha Carter (Sold 40 000 shares of value $1 669 550 ), Pamela Stephenson (Sold 1 308 shares of value $45 171 ), Patrick Taylor Horn (Sold 382 shares of value $10 854 ), Simon N.R. Harford (Sold 292 shares of value $9 815 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.